{"id":"https://openalex.org/W2008180913","doi":"https://doi.org/10.1310/hct0705-229","title":"Pilot Study of Once-Daily Simplification Therapy with Abacavir/Lamivudine/Zidovudine and Efavirenz for Treatment of HIV-1 Infection","display_name":"Pilot Study of Once-Daily Simplification Therapy with Abacavir/Lamivudine/Zidovudine and Efavirenz for Treatment of HIV-1 Infection","publication_year":2006,"publication_date":"2006-01-01","ids":{"openalex":"https://openalex.org/W2008180913","doi":"https://doi.org/10.1310/hct0705-229","mag":"2008180913","pmid":"https://pubmed.ncbi.nlm.nih.gov/17162316"},"language":"en","primary_location":{"id":"doi:10.1310/hct0705-229","doi":"https://doi.org/10.1310/hct0705-229","is_oa":true,"landing_page_url":"https://doi.org/10.1310/hct0705-229","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1310/hct0705-229?needAccess=true","source":{"id":"https://openalex.org/S13415641","display_name":"HIV Clinical Trials","issn_l":"1528-4336","issn":["1528-4336","1945-5771"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","jufo-1","poland-70"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"HIV Clinical Trials","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://www.tandfonline.com/doi/pdf/10.1310/hct0705-229?needAccess=true","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5089993955","display_name":"Peter Jerome Ruane","orcid":"https://orcid.org/0000-0002-7170-9928","observed_orcids":["https://orcid.org/0000-0002-7170-9928"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Peter Ruane","raw_affiliation_strings":["Private Practice, Los Angeles, California, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Private Practice, Los Angeles, California, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025642129","display_name":"Joseph Lang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joseph Lang","raw_affiliation_strings":["ID ConsultantsCharlotte, North Carolina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ID ConsultantsCharlotte, North Carolina","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103806974","display_name":"Edwin DeJesus","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210120784","display_name":"Orlando Immunology Center","ror":"https://ror.org/02cj88v79","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210120784"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Edwin DeJesus","raw_affiliation_strings":["Orlando Immunology CenterOrlando, Florida"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Orlando Immunology CenterOrlando, Florida","institution_ids":["https://openalex.org/I4210120784"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103693249","display_name":"Daniel S Berger","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Daniel S. Berger","raw_affiliation_strings":["Northstar Medical CenterChicago, Illinois"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Northstar Medical CenterChicago, Illinois","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041570571","display_name":"Robin Henry Dretler","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Robin Dretler","raw_affiliation_strings":["ID SpecialistsAtlanta, Georgia"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"ID SpecialistsAtlanta, Georgia","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015290437","display_name":"Allan E. Rodriguez","orcid":"https://orcid.org/0000-0001-9477-3327","observed_orcids":["https://orcid.org/0000-0001-9477-3327"]},"institutions":[{"id":"https://openalex.org/I145608581","display_name":"University of Miami","ror":"https://ror.org/02dgjyy92","country_code":"US","type":"education","lineage":["https://openalex.org/I145608581"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Allan Rodriguez","raw_affiliation_strings":["University of MiamiMiami, Florida"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of MiamiMiami, Florida","institution_ids":["https://openalex.org/I145608581"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103367960","display_name":"Douglas J. Ward","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Douglas J. Ward","raw_affiliation_strings":["Dupont Circle Physicians Group, Washington, DC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Dupont Circle Physicians Group, Washington, DC","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103572181","display_name":"Michael L. Lim","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Michael L. Lim","raw_affiliation_strings":["GlaxoSmithKlineHIV-Infectious Diseases Medicine Development Center, Research Triangle Park, North Carolina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKlineHIV-Infectious Diseases Medicine Development Center, Research Triangle Park, North Carolina","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088607533","display_name":"Qiming Liao","orcid":"https://orcid.org/0000-0001-5822-2739","observed_orcids":["https://orcid.org/0000-0001-5822-2739"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Qiming Liao","raw_affiliation_strings":["GlaxoSmithKlineHIV-Infectious Diseases Medicine Development Center, Research Triangle Park, North Carolina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKlineHIV-Infectious Diseases Medicine Development Center, Research Triangle Park, North Carolina","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023694817","display_name":"Sunila Reddy","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sunila Reddy","raw_affiliation_strings":["GlaxoSmithKlineHIV-Infectious Diseases Medicine Development Center, Research Triangle Park, North Carolina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKlineHIV-Infectious Diseases Medicine Development Center, Research Triangle Park, North Carolina","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034571044","display_name":"Marty St. Clair","orcid":"https://orcid.org/0000-0002-2221-2181","observed_orcids":["https://orcid.org/0000-0002-2221-2181"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marty St. Clair","raw_affiliation_strings":["GlaxoSmithKlineHIV-Infectious Diseases Medicine Development Center, Research Triangle Park, North Carolina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKlineHIV-Infectious Diseases Medicine Development Center, Research Triangle Park, North Carolina","institution_ids":["https://openalex.org/I4210114143"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108785116","display_name":"Tania Vila","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tania Vila","raw_affiliation_strings":["University of North Carolina, School of Pharmacy, Chapel Hill, North Carolina, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of North Carolina, School of Pharmacy, Chapel Hill, North Carolina, USA","institution_ids":["https://openalex.org/I114027177"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5079973774","display_name":"Mark S. Shaefer","orcid":"https://orcid.org/0000-0002-0545-7304","observed_orcids":["https://orcid.org/0000-0002-0545-7304"]},"institutions":[{"id":"https://openalex.org/I4210114143","display_name":"GlaxoSmithKline (United States)","ror":"https://ror.org/025vn3989","country_code":"US","type":"company","lineage":["https://openalex.org/I188950975","https://openalex.org/I4210114143"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark S. Shaefer","raw_affiliation_strings":["GlaxoSmithKlineHIV-Infectious Diseases Medicine Development Center, Research Triangle Park, North Carolina"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKlineHIV-Infectious Diseases Medicine Development Center, Research Triangle Park, North Carolina","institution_ids":["https://openalex.org/I4210114143"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5103572181"],"corresponding_institution_ids":["https://openalex.org/I4210114143"],"apc_list":null,"apc_paid":null,"fwci":0.8219,"has_fulltext":true,"cited_by_count":9,"citation_normalized_percentile":{"value":0.74153834,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"7","issue":"5","first_page":"229","last_page":"236"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10082","display_name":"HIV/AIDS Research and Interventions","score":0.0019000000320374966,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/hiv-1-infection","display_name":"HIV-1 infection","score":0.9179999828338623},{"id":"https://openalex.org/keywords/once-daily-dosing","display_name":"once-daily dosing","score":0.9079999923706055},{"id":"https://openalex.org/keywords/efavirenz","display_name":"efavirenz","score":0.9340000152587891},{"id":"https://openalex.org/keywords/fixed-dose-combination-antiretroviral-therapy","display_name":"fixed-dose combination antiretroviral therapy","score":0.8970000147819519},{"id":"https://openalex.org/keywords/antiretroviral-therapy-adherence","display_name":"antiretroviral therapy adherence","score":0.7099999785423279},{"id":"https://openalex.org/keywords/viral-suppression","display_name":"viral suppression","score":0.7979999780654907},{"id":"https://openalex.org/keywords/cd4-count","display_name":"CD4 count","score":0.8870000243186951},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.6179999709129333},{"id":"https://openalex.org/keywords/treatment-switching","display_name":"treatment switching","score":0.3089999854564667}],"concepts":[{"id":"https://openalex.org/C2777869810","wikidata":"https://www.wikidata.org/wiki/Q422631","display_name":"Lamivudine","level":4,"score":0.912973940372467},{"id":"https://openalex.org/C2780216070","wikidata":"https://www.wikidata.org/wiki/Q198504","display_name":"Zidovudine","level":4,"score":0.9099262952804565},{"id":"https://openalex.org/C2779465607","wikidata":"https://www.wikidata.org/wiki/Q304330","display_name":"Abacavir","level":5,"score":0.9092317819595337},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.884170413017273},{"id":"https://openalex.org/C2781432083","wikidata":"https://www.wikidata.org/wiki/Q422645","display_name":"Efavirenz","level":5,"score":0.8517023324966431},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.6217440962791443},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5448697209358215},{"id":"https://openalex.org/C142462285","wikidata":"https://www.wikidata.org/wiki/Q2528140","display_name":"Viral load","level":3,"score":0.5038453936576843},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.4859005808830261},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.32052111625671387},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.25736188888549805},{"id":"https://openalex.org/C2993143319","wikidata":"https://www.wikidata.org/wiki/Q583050","display_name":"Antiretroviral therapy","level":4,"score":0.18642562627792358},{"id":"https://openalex.org/C2780727368","wikidata":"https://www.wikidata.org/wiki/Q1928978","display_name":"Viral disease","level":3,"score":0.09560921788215637},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.06298652291297913},{"id":"https://openalex.org/C2780593183","wikidata":"https://www.wikidata.org/wiki/Q6844","display_name":"Hepatitis B virus","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D000099227","descriptor_name":"Abacavir","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000480","descriptor_name":"Alkynes","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003521","descriptor_name":"Cyclopropanes","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009325","descriptor_name":"Nausea","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D010078","descriptor_name":"Oxazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D010078","descriptor_name":"Oxazines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D010078","descriptor_name":"Oxazines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D010865","descriptor_name":"Pilot Projects","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012367","descriptor_name":"RNA, Viral","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D013607","descriptor_name":"Tablets","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015215","descriptor_name":"Zidovudine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D015215","descriptor_name":"Zidovudine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D015215","descriptor_name":"Zidovudine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D015224","descriptor_name":"Dideoxynucleosides","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D015224","descriptor_name":"Dideoxynucleosides","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D015224","descriptor_name":"Dideoxynucleosides","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000821","qualifier_name":"virology","is_major_topic":false},{"descriptor_ui":"D015746","descriptor_name":"Abdominal Pain","qualifier_ui":"Q000209","qualifier_name":"etiology","is_major_topic":false},{"descriptor_ui":"D016312","descriptor_name":"Treatment Refusal","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017211","descriptor_name":"Treatment Failure","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D019259","descriptor_name":"Lamivudine","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D019259","descriptor_name":"Lamivudine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D019259","descriptor_name":"Lamivudine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D048588","descriptor_name":"Benzoxazines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1310/hct0705-229","doi":"https://doi.org/10.1310/hct0705-229","is_oa":true,"landing_page_url":"https://doi.org/10.1310/hct0705-229","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1310/hct0705-229?needAccess=true","source":{"id":"https://openalex.org/S13415641","display_name":"HIV Clinical Trials","issn_l":"1528-4336","issn":["1528-4336","1945-5771"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","jufo-1","poland-70"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"HIV Clinical Trials","raw_type":"journal-article"},{"id":"doi:10.1310/q457-57lp-2387-671w","doi":"https://doi.org/10.1310/q457-57lp-2387-671w","is_oa":false,"landing_page_url":"https://doi.org/10.1310/q457-57lp-2387-671w","pdf_url":null,"source":{"id":"https://openalex.org/S13415641","display_name":"HIV Clinical Trials","issn_l":"1528-4336","issn":["1528-4336","1945-5771"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","jufo-1","poland-70"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"HIV Clinical Trials","raw_type":"journal-article"},{"id":"pmid:17162316","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17162316","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"HIV clinical trials","raw_type":"Clinical Trial"}],"best_oa_location":{"id":"doi:10.1310/hct0705-229","doi":"https://doi.org/10.1310/hct0705-229","is_oa":true,"landing_page_url":"https://doi.org/10.1310/hct0705-229","pdf_url":"https://www.tandfonline.com/doi/pdf/10.1310/hct0705-229?needAccess=true","source":{"id":"https://openalex.org/S13415641","display_name":"HIV Clinical Trials","issn_l":"1528-4336","issn":["1528-4336","1945-5771"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","jufo-1","poland-70"],"host_organization":"https://openalex.org/P4310320547","host_organization_name":"Taylor & Francis","host_organization_lineage":["https://openalex.org/P4310320547","https://openalex.org/P4310320449"],"host_organization_lineage_names":["Taylor & Francis","Informa"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"HIV Clinical Trials","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320307115","display_name":"Bristol-Myers Squibb","ror":"https://ror.org/00gtmwv55"},{"id":"https://openalex.org/F4320307773","display_name":"GlaxoSmithKline","ror":"https://ror.org/01xsqw823"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2008180913.pdf","grobid_xml":"https://content.openalex.org/works/W2008180913.grobid-xml"},"referenced_works_count":10,"referenced_works":["https://openalex.org/W1978540833","https://openalex.org/W1998188886","https://openalex.org/W2008989084","https://openalex.org/W2028113159","https://openalex.org/W2061857819","https://openalex.org/W2083477796","https://openalex.org/W2146329405","https://openalex.org/W2164099498","https://openalex.org/W2318289184","https://openalex.org/W2321852728"],"related_works":["https://openalex.org/W2074870577","https://openalex.org/W1998188886","https://openalex.org/W2061857819","https://openalex.org/W1997259446","https://openalex.org/W2083477796","https://openalex.org/W1993086185","https://openalex.org/W2067923558","https://openalex.org/W2093984759","https://openalex.org/W2053053844","https://openalex.org/W2410311867"],"abstract_inverted_index":{"OBJECTIVE:":[0],"The":[1],"purpose":[2],"of":[3,14,67,118,161,329,338,352],"this":[4,242,326],"pilot":[5,327],"study":[6,46,252,328],"was":[7,40,147,157,203,263],"to":[8,113,115,188,219,314,341,350],"explore":[9],"the":[10,15,58,108,164,170,207,220,250,267],"efficacy":[11],"and":[12,88,104,138,167,210,235,276,284,300,317],"safety":[13],"abacavir/lamivudine/zidovudine":[16,68,119,258,333,342,355],"fixed-dose":[17],"combination":[18,34],"tablet":[19,29],"administered":[20],"as":[21],"two":[22],"tablets":[23,117],"once":[24],"daily":[25,31],"(qd)":[26],"versus":[27],"one":[28],"twice":[30],"(bid)":[32],"in":[33,52,57,163,169,266],"with":[35,47,78,286],"efavirenz":[36],"(EFV).":[37],"METHOD:":[38],"This":[39],"a":[41,48,89],"prospective,":[42],"randomized,":[43],"open-label,":[44],"multicenter":[45],"24-week":[49],"treatment":[50,129],"period":[51],"7":[53],"outpatient":[54],"HIV":[55],"clinics":[56],"United":[59],"States.":[60],"Patients":[61],"currently":[62],"receiving":[63,256],"an":[64],"initial":[65],"regimen":[66],"bid":[69,334,356],"plus":[70,121,335,344,357],"EFV":[71,122,248,345],"qd":[72,120,123,259,343],"for":[73,83,132,159,182,206,213,306],"at":[74,84,232],"least":[75,85],"6":[76],"months":[77,87],"HIV-1":[79,153,228],"RNA":[80,154,229],"<50":[81,155],"copies/mL":[82,156],"3":[86],"screening":[90],"CD4+":[91,144,197],"cell":[92,145,198],"count":[93,146,199],">":[94,184],"or":[95,126,185],"=":[96,176,186,191],"200":[97],"cells/mm3":[98,205,212],"were":[99,111,140,282,294,322],"eligible.":[100],"Thirty-six":[101],"patients":[102,311,330],"enrolled,":[103],"35":[105],"(97%)":[106],"completed":[107],"study.":[109],"Participants":[110],"randomized":[112,218],"switch":[114],"2":[116],"(QD":[124],"arm)":[125,131],"continue":[127],"current":[128],"(BID":[130],"24":[133],"weeks.":[134],"RESULTS:":[135],"Efficacy,":[136],"safety,":[137],"adherence":[139,262],"evaluated.":[141],"Median":[142,261],"baseline":[143,202],"521":[148],"cells/mm3.":[149],"At":[150,193],"week":[151,194,233],"24,":[152,195],"achieved":[158],"94%":[160,337],"participants":[162,339,353],"QD":[165,208,221,268],"arm":[166,172,209,222],"89%":[168,351],"BID":[171,214],"by":[173],"intent-to-treat,":[174],"missing":[175],"failure":[177,225],"analysis":[178],"(95%":[179],"confidence":[180],"interval":[181],"difference:":[183],"0.29":[187],"+0.18,":[189],"p":[190],"1.000).":[192],"median":[196],"change":[200],"from":[201],"+26":[204],"-39":[211],"arm.":[215],"One":[216],"patient":[217,243,304],"met":[223],"virologic":[224,347],"criteria":[226],"(confirmed":[227],">120":[230],"copies/mL)":[231],"20":[234],"viral":[236],"genotype":[237],"showed":[238],"M184V.":[239],"After":[240],"failure,":[241],"revealed":[244],"he":[245],"never":[246],"took":[247],"throughout":[249],"entire":[251],"after":[253],"randomization,":[254],"effectively":[255],"only":[257],"alone.":[260],"slightly":[264],"higher":[265],"arm,":[269],"although":[270],"both":[271],"arms":[272],"had":[273],"broad":[274],"variability":[275],"overlapping":[277],"interquartile":[278],"ranges.":[279],"Adverse":[280],"events":[281,293],"infrequent":[283],"occurred":[285],"similar":[287],"frequency":[288],"between":[289],"arms;":[290],"treatment-related":[291],"adverse":[292,308,315],"abdominal":[295],"pain,":[296],"flatulence,":[297],"nausea,":[298],"headache,":[299],"abnormal":[301],"dreams":[302],"(1":[303],"[3%]":[305],"each":[307],"event).":[309],"No":[310],"withdrew":[312],"due":[313],"events,":[316],"no":[318],"abacavir":[319],"hypersensitivity":[320],"reactions":[321],"reported.":[323],"CONCLUSION:":[324],"In":[325],"suppressed":[331],"on":[332],"EFV,":[336],"switching":[340],"maintained":[346],"suppression,":[348],"compared":[349],"continuing":[354],"EFV.":[358]},"counts_by_year":[{"year":2015,"cited_by_count":1},{"year":2014,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}